Zestoretic 20mg/12.5mg Tablets Malta - engelsk - Malta Medicines Authority

zestoretic 20mg/12.5mg tablets

atnahs pharma netherlands b.v. copenhagen towers Ørestads boulevard 108, 5.tv dk-2300 københavn s , denmark - hydrochlorothiazide, lisinopril dihydrate - tablet - hydrochlorothiazide 12.5 mg lisinopril dihydrate 20 mg - agents acting on the renin-angiotensin system

Vancomycin 1000 mg powder for concentrate for solution for infusion Irland - engelsk - HPRA (Health Products Regulatory Authority)

vancomycin 1000 mg powder for concentrate for solution for infusion

fresenius kabi deutschland gmbh - vancomycin hydrochloride - powder for concentrate for solution for infusion - 1000 milligram(s) - glycopeptide antibacterials; vancomycin

Vancomycin 500 mg powder for concentrate for solution for infusion Irland - engelsk - HPRA (Health Products Regulatory Authority)

vancomycin 500 mg powder for concentrate for solution for infusion

fresenius kabi deutschland gmbh - vancomycin hydrochloride - powder for concentrate for solution for infusion - 500 milligram(s) - glycopeptide antibacterials; vancomycin

Nabumetone Tillomed 500 mg Film-coated Tablets Irland - engelsk - HPRA (Health Products Regulatory Authority)

nabumetone tillomed 500 mg film-coated tablets

tillomed pharma gmbh - nabumetone - film-coated tablet - 500 milligram(s) - other antiinflammatory and antirheumatic agents, non-steroids; nabumetone

Vesanoid 10 mg soft capsules Irland - engelsk - HPRA (Health Products Regulatory Authority)

vesanoid 10 mg soft capsules

cheplapharm arzneimittel gmbh - tretinoin - capsule, soft - 10 milligram(s) - cytostatic-differentiating agent

Xenical Den europeiske union - engelsk - EMA (European Medicines Agency)

xenical

cheplapharm arzneimittel gmbh - orlistat - obesity - antiobesity preparations, excl. diet products - xenical is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (bmi) greater or equal to 30 kg/m2, or overweight patients (bmi > 28 kg/m2) with associated risk factors.treatment with orlistat should be discontinued after 12 weeks if patients have been unable to lose at least 5% of the body weight as measured at the start of therapy.

Medical device cleaning agent Australia - engelsk - Department of Health (Therapeutic Goods Administration)

medical device cleaning agent

device technologies australia pty ltd - 63385 - medical device cleaning agent - detergent for cleaning of medical devices.